Vigil Neuroscience(VIGL) GlobeNewswire·2025-01-08 21:05Core Insights - Vigil Neuroscience is on track to report data from the Phase 1 clinical trial of VG-3927 for Alzheimer's disease in the first quarter of 2025 and final analysis from the IGNITE Phase 2 clinical trial of iluzanebart in ALSP is planned for the second quarter of 2025 [1][12] 2024 Key Achievements - The company secured a $40 million strategic investment from Sanofi to fund research and development activities [5] - Completed enrollment of 20 patients for the IGNITE Phase 2 clinical trial, exceeding the initial target of 15 patients [6] - Surpassed enrollment of 50 participants in the ILLUMINATE natural history study of ALSP, providing critical insights on MRI and NfL biomarkers [6] - Reported interim data from the ongoing Phase 1 clinical trial of VG-3927, demonstrating safety, tolerability, and pharmacokinetic profiles [6] - FDA removed the partial clinical hold on the Phase 1 clinical trial of VG-3927 based on a complete response submitted by the company [6] - Presented new preclinical data on VG-3927 at the Alzheimer’s Association International Conference, highlighting its differentiated mechanism of action compared to antibody TREM2 agonists [6] 2025 Milestones - The company plans to report key data for both VG-3927 and iluzanebart in the first half of 2025, which are expected to support efforts to bring transformative therapies to patients with ALSP and Alzheimer's disease [9] - The final analysis of the IGNITE Phase 2 clinical trial is planned for the second quarter of 2025, with the company pursuing an accelerated approval pathway for iluzanebart in ALSP [12]